Media stories about Cardiome Pharma Corporation (NASDAQ:CRME) (TSE:COM) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cardiome Pharma Corporation earned a daily sentiment score of 0.06 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.3955217825922 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
CRME has been the topic of several research reports. Zacks Investment Research cut shares of Cardiome Pharma Corporation from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Canaccord Genuity restated a “buy” rating and issued a $8.00 price target on shares of Cardiome Pharma Corporation in a research report on Monday, July 17th. ValuEngine upgraded shares of Cardiome Pharma Corporation from a “sell” rating to a “hold” rating in a research report on Thursday, July 27th. Finally, HC Wainwright set a $10.00 price target on shares of Cardiome Pharma Corporation and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $5.90.
Shares of Cardiome Pharma Corporation (NASDAQ:CRME) traded up 2.60% during midday trading on Wednesday, reaching $2.37. 39,526 shares of the company traded hands. The firm’s market capitalization is $80.11 million. The stock has a 50 day moving average price of $3.33 and a 200 day moving average price of $3.55. Cardiome Pharma Corporation has a 1-year low of $2.09 and a 1-year high of $4.84.
Cardiome Pharma Corporation (NASDAQ:CRME) (TSE:COM) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.08). The firm had revenue of $5.75 million during the quarter, compared to analysts’ expectations of $6.88 million. Cardiome Pharma Corporation had a negative net margin of 110.95% and a negative return on equity of 78.51%. The company’s revenue for the quarter was down 2.5% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.37) EPS. Analysts expect that Cardiome Pharma Corporation will post ($0.69) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This story was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.chaffeybreeze.com/2017/09/13/cardiome-pharma-corporation-crme-getting-somewhat-favorable-news-coverage-report-finds.html.
Cardiome Pharma Corporation Company Profile
Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome.
Receive News & Ratings for Cardiome Pharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma Corporation and related companies with MarketBeat.com's FREE daily email newsletter.